Skip to main
DYAI
DYAI logo

DYAI Stock Forecast & Price Target

DYAI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dyadic International Inc. has reported substantial revenue growth in its 3Q24 financial results, attributed to increased interest in its gene expression platform, C1, and the proprietary Dapibus technology, both of which have gained traction in licensing agreements. The company recognized $1 million in licensing revenue from a deal with PHB and an additional success fee of $425,000 from Inzymes ApS for developing non-animal dairy enzymes. This positive momentum reflects Dyadic's strategic positioning to capitalize on the rising demand for cost-effective production of biologic products, such as therapeutics and vaccines, enhancing its prospects for future growth.

Bears say

Dyadic International Inc. reported a net loss of $0.2 million in the third quarter of 2024, indicating ongoing financial struggles as the company continues to invest in its biotechnology platform. The company faces significant risks, including the possibility of unsuccessful clinical trials and the challenges associated with regulatory requirements for further studies, which could hinder its commercialization efforts. Additionally, there are concerns regarding the company’s ability to differentiate its products competitively, potential issues with intellectual property rights, and the risk of needing to secure additional funding under adverse market conditions.

DYAI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyadic International Inc., DE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyadic International Inc., DE (DYAI) Forecast

Analysts have given DYAI a Strong Buy based on their latest research and market trends.

According to 1 analysts, DYAI has a Strong Buy consensus rating as of Jun 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyadic International Inc., DE (DYAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.